The company has nominated a member of this class, the orally available, small-molecule brain-penetrant NLRP3 inhibitor BGE-102, as a development candidate. The structurally novel drug has potential best-in-class features, including high potency and high brain penetration, an important attribute for a compound that could be used for treatment of neuroinflammation linked to conditions such as obesity. IND-enabling experiments for BGE-102 are being conducted as of Q1 2025, and Phase I SAD data are anticipated by the end of 2025.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze